GlycoUniverse GmbH & Co. KGaA

What GlycoUniverse GmbH & Co. KGaA does

GlycoUniverse GmbH & Co. KGaA is a Potsdam, Germany-based life science tools company founded in 2013 that specializes in automated carbohydrate synthesis and glycan reagents. Its flagship product is the Glyconeer®, marketed as the world's first commercial automated oligosaccharide synthesizer, capable of producing carbohydrate chains from 2-mer to 200-mer in length. The instrument is produced under exclusive licensing agreements with MIT (Patent PCT/US2001/025859, licensed since 2013) and the Max-Planck-Institute (Patents PCT/EP2020/080922, /080979, /080964, licensed since 2022). Around the instrument, the company has built a catalog of over 1,000 glycan standards covering monosaccharides (fucose, galactose, glucose, mannose, sialic acid, etc.), oligosaccharides (blood group antigens, human milk oligosaccharides, gangliosides, alpha-Gal, glycosaminoglycans), and glycoconjugates/resins (glycoaminoacids, glycopeptides, photocleavable resins, sulfation products), as well as glycan arrays, analytical services, custom synthesis, and training offerings.

The company operates a direct-to-researcher go-to-market: it sells the Glyconeer® as capital equipment (20 units delivered to date), distributes catalog products through its own e-commerce storefront with global shipping, and engages customers directly on bespoke custom synthesis and analytical projects (over 100 projects and FTEs completed). Customers are primarily academic research institutions and pharmaceutical/biotechnology companies working on carbohydrate-based drug discovery, biomarker research, therapeutic development, and quality control. The company has delivered products and instruments to 14 countries spanning Europe, North America, Asia Pacific, the Middle East, and South Asia. Despite this global footprint, GlycoUniverse remains a micro-entity with 6 employees, no disclosed external funding, and a German KGaA (Kommanditgesellschaft auf Aktien) legal structure.

Name

GlycoUniverse GmbH & Co. KGaA

Legal name

GlycoUniverse GmbH & Co. KGaA

Website

https://glycouniverse.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

GlycoUniverse GmbH & Co. KGaA is a Potsdam, Germany-based life science tools company that produces the Glyconeer®, the world's first commercial automated oligosaccharide synthesizer, and supplies over 1,000 glycan standards and custom synthesis services to academic and pharmaceutical researchers globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Potsdam

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Glyconeer® Synthesizer Sales: Sale of the Glyconeer® automated oligosaccharide synthesizer - the world's first commercial automated synthesizer for oligosaccharides. Twenty units have been delivered to international research centers, universities, and companies.
2. Glycan Products Catalog: Sale of fine glycan standards and life science products through e-commerce platform. Product categories include monosaccharides, oligosaccharides, and glycoconjugates with over 1000 products available.
3. Custom Synthesis Services: Bespoke carbohydrate synthesis services for challenging synthetic and analytical projects, including step-by-step planning, validation, and confidentiality protocols.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

GlycoUniverse manufactures and sells the Glyconeer®, the world's first commercial automated oligosaccharide synthesizer (produced under exclusive licenses from MIT and Max-Planck-Institute), along with a catalog of over 1,000 glycan products (monosaccharides, oligosaccharides, and glycoconjugates). The company also provides custom carbohydrate synthesis services, glycan analysis, glycan arrays, and training to researchers in academia and industry worldwide.

Product overview

GlycoUniverse GmbH & Co. KGaA is a provider of carbohydrate-based life science products and services. The company operates around its flagship product, the Glyconeer® — the world's first commercial automated oligosaccharide synthesizer — supported by an extensive portfolio of glycan products (including over 1000 products), glycan arrays, and glycan analysis services. The product portfolio includes Monosaccharides, Oligosaccharides (Blood Group Antigens, Human Milk Oligosaccharides, Gangliosides), and Glycoconjugates & Resins. The company also offers Custom Synthesis services for challenging synthetic projects and Training services. The core Glyconeer® synthesizer is complemented by a catalog of fine glycan standards and life science products for scientists in both industry and academia.

Differentiator

Problem solved

Functional benefit

Brands

• Glyconeer®: World's first commercial automated oligosaccharide synthesizer produced by GlycoUniverse under exclusive licensing from MIT and Max-Planck-Institute.

Products and services

• Glyconeer® Automated Oligosaccharide Synthesizer The world's first commercial automated oligosaccharide synthesizer that enables automated synthesis of carbohydrate chains from 2-mer to 200-mer length. Sold to academic research centers, universities, and life science companies for carbohydrate-based research and synthesis applications.
• Glycan Products Catalog

Quantifiable outcome

• Zero contamination processing ensures highest quality glycan standards for research accuracy

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Max-Planck-InstitutecoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Exclusive licensing partnership with Max-Planck-Institute for additional oligosaccharide synthesis patents (PCT/EP2020/080922; PCT/EP2020/080979; PCT/EP2020/080964) since 2022. This partnership enhances GlycoUniverse's technology portfolio for the Glyconeer® platform.
• MIT (Massachusetts Institute of Technology)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2013Exclusive licensing partnership with MIT for automated oligosaccharide synthesizer technology (Patent: PCT/US2001/025859) since 2013. This partnership enables GlycoUniverse to manufacture and commercialize the world's first automated oligosaccharide synthesizer under MIT's patent protection.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Danaher Corporation (Beckman Coulter, Cytiva, Leica): Diversified life sciences and diagnostics platform owner. Relevant as a potential acquirer or competitor in bioprocessing, analytical instruments, and life-science reagents adjacent to GlycoUniverse's instrument-plus-consumables model.
• Bio-Rad Laboratories: US life science research and clinical diagnostics company with significant presence in reagents, instruments, and consumables. Comparable go-to-market and customer overlap with GlycoUniverse's academic and pharma research base.
• Thermo Fisher Scientific: Global life sciences tools and reagents leader with broad portfolios in analytical instruments and biochemistry consumables. Represents the scale competitor that could enter automated glycan synthesis if the market scales.
• Agilent Technologies: Major analytical instrument and life science reagent provider with strong presence in chromatography, mass spectrometry, and biochemistry. Indirectly competes through instruments used in glycan analysis workflows.

Regional players

• Sartorius AG: Germany-headquartered bioprocessing and life science tools supplier serving pharma and academic research. Comparable German-domiciled life science tools company with similar end-customers, though operating at much greater scale.

Direct peers

• Biosynth (formerly Carbosynth): Switzerland-headquartered supplier of carbohydrates, nucleosides, and life science reagents with extensive custom synthesis services. Closely overlaps GlycoUniverse's product catalog, custom synthesis, and academic/pharma customer base.
• Dextra Laboratories: UK-based specialist in carbohydrate chemistry, oligosaccharide synthesis, and custom glycan services for research and pharma. Competes directly with GlycoUniverse's custom synthesis and glycan product offerings.
• Elicityl: French specialty manufacturer of carbohydrates, oligosaccharides, and glyco-conjugates serving pharma and academic research. Directly comparable to GlycoUniverse's catalog and custom synthesis business in the glycoscience reagent market.
• Omicron Biochemicals: US-based supplier of rare sugars, isotopically labeled carbohydrates, and custom synthesis services. Comparable to GlycoUniverse as a specialist carbohydrate chemistry supplier for life science research.
• GlycoTech Corporation: US-based supplier of glycan reagents, neoglycoproteins, and glycan arrays for glycobiology research. Directly overlaps GlycoUniverse's glycan products and glycan array offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/glycouniverse
• LinkedInlinkedin.com/company/glycouniverse
• Instagraminstagram.com/glycouniverse

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlycoUniverse GmbH & Co. KGaA